RxDoctor Payments Data

Jennifer Green, APRN

Adult Health · Bluffton, SCNPI 1013030824

Payments from drug & device makers

$2,487in general payments, 2019–2025

Across 116 payments — averaging $21.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Abbott$589
  • AstraZeneca$184
  • Hologic Sales And Service, LLC$134
  • Lilly USA, LLC$104
  • Novo Nordisk$88
  • plus $313 from 9 others

What the payments were for

  • Food & beverage$2,487100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,487 in reported general payments places this provider in the 70th percentile of 292 adult health providers in South Carolina.

See all adult health providers in South Carolina

Medicare billing

Part B allowed, 2024
$106,524
Medicare patients
258
Services billed
1,551

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide256$275,275
OzempicSemaglutide79$76,776
EntrestoSacubitril/Valsartan43$31,199
FarxigaDapagliflozin Propanediol32$29,991
VraylarCariprazine Hcl14$19,679
EliquisApixaban18$13,720
SymbicortBudesonide/Formoterol Fumarate34$9,346
Tresiba Flextouch U-100Insulin Degludec12$7,233
Breo ElliptaFluticasone/Vilanterol11$5,802
Lantus SolostarInsulin Glargine,hum.Rec.Anlog59$5,647
Rosuvastatin Calcium372$5,314
SynthroidLevothyroxine Sodium60$4,931
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate11$3,684
Levothyroxine Sodium325$3,542
Paroxetine Hcl28$3,359

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$104$275,275256 claims
Novo NordiskOzempic$88$76,77679 claims
AstraZenecaFarxiga, Symbicort$184$39,33766 claims
AbbVieVraylar, Synthroid$1,074$24,61074 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 292 adult health providers in South Carolina.

Other adult health in Bluffton

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →